BioMark is proud to partner and cooperate with National Cancer Institute in Bangladesh and BioMark China in a phase III multi site trial. The trail will involve over 400 subjects and will focus on 4 cancer indications. All the procedures will follow North American regulatory guidelines that were prepared by Saint Boniface Research centre’s regulatory group.
News
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify Biomarkers for NEN
BioMark Diagnostics and Principal Investigators Publish an Important Approach Using Metabolomics and ML to Identify
October 1, 2024
